Persistence of Antibody Response to N. Meningitidis Group C in Children

Novartis

Status and phase: Completed; Phase 4

Conditions: Prevention of Meningococcal Infection

Treatments: Biological: Meningococcal C conjugate vaccine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00316654

V14P38E1

2004-001522-24 (EudraCT Number)

Details and patient eligibility

About

Persistence of Antibody Response to N. meningitidis Group C in Children

Enrollment: 489 patients

Sex: All

Ages: 7+ months old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy children

Exclusion criteria

• previous ascertained or suspected disease caused by N. meningitidis
• previous significant acute or chronic infections
• any other serious disease

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)